Home Cart Sign in  
Chemical Structure| 548472-68-0 Chemical Structure| 548472-68-0

Structure of Nutlin-3
CAS No.: 548472-68-0

Chemical Structure| 548472-68-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Nutlin-3 is a commercially available p53-MDM2 inhibitor with a Ki of 90 nM.

Synonyms: (±)-Nutlin-3

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Nutlin-3

CAS No. :548472-68-0
Formula : C30H30Cl2N4O4
M.W : 581.49
SMILES Code : O=C1NCCN(C(N2[C@@H](C3=CC=C(Cl)C=C3)[C@@H](C4=CC=C(Cl)C=C4)N=C2C5=CC=C(OC)C=C5OC(C)C)=O)C1
Synonyms :
(±)-Nutlin-3
MDL No. :MFCD07784509
InChI Key :BDUHCSBCVGXTJM-UHFFFAOYSA-N
Pubchem ID :216345

Safety of Nutlin-3

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
MOLM-13 cells 6 µM 0, 2, 4, 6, 8 hours Nutlin-3 enhances p53 acetylation and increases levels of p53, MDM2, and p21 PMC4032636
PAEC 10 µM 24 hours Nutlin-3 increased p53 and induced the formation of the PPARγ-p53 complex, assessed by immunoprecipitation with either anti-PPARγ or anti-p53 antibodies. PMC7908816
293T cells 0.5mg/L 24 hours Increased p53 transcriptional activity induced by Dox was partially dependent on PPARγ. PMC7908816
MDA-MB 435S (breast cancer cells) 30 µM 24 hours Nutlin-3 enhances the bortezomib sensitivity of p53-defective cancer cells by inducing paraptosis, leading to cell death. PMC5579507
DLD-1 (colon cancer cells) 30 µM 24 hours Nutlin-3 enhances the bortezomib sensitivity of p53-defective cancer cells by inducing paraptosis, leading to cell death. PMC5579507
HeLa (cervical cancer cells) 30 µM 24 hours Nutlin-3 enhances the bortezomib sensitivity of p53-defective cancer cells by inducing paraptosis, leading to cell death. PMC5579507
T98G (glioblastoma cells) 30 µM 24 hours Nutlin-3 enhances the bortezomib sensitivity of p53-defective cancer cells by inducing paraptosis, leading to cell death. PMC5579507
RT4 schwannoma cells 0-10 μM 24, 48, 72 hours Nutlin-3 inhibited the proliferation of schwannoma cells through a cooperative recovery of merlin and p53, accompanied by the shuttling of both proteins from the cytoplasm to the nucleus. PMC6197711
HEI-193 schwannoma cells 0-10 μM 24, 48, 72 hours Nutlin-3 combined with MG-132 significantly inhibited the growth of schwannoma cells through coordinated reactivation of p53. PMC6197711
SAOS-2 cells 6 µM 4, 6 hours Nutlin-3 enhances p53 acetylation in SAOS-2 cells, with acetylation levels higher than the increase in total p53 levels PMC4032636
H1299 cells 6 µM 6 hours Nutlin-3 significantly increases p53 acetylation levels in H1299 cells, with only a small increase in total p53 levels PMC4032636
94T778 cells 10 μM 72 hours Nutlin-3 treatment effectively stabilized p53 and upregulated direct p53 targets MDM2, p21, and PUMA. Under these conditions, most liposarcoma cells underwent cell-cycle arrest, with approximately 20% of cells undergoing apoptosis. PMC10391328
Lipo-246 cells 10 μM 72 hours Nutlin-3 treatment effectively stabilized p53 and upregulated direct p53 targets MDM2, p21, and PUMA. Under these conditions, most liposarcoma cells underwent cell-cycle arrest, with approximately 20% of cells undergoing apoptosis. PMC10391328
Z-138 5 μM 8 h Nutlin-3 resulted in a reduction in cell proliferation/viability, an increase in the apoptotic fraction, and cell cycle arrest PMC7322626
Granta 519 10 μM 8 h Nutlin-3 resulted in a reduction in cell proliferation/viability, an increase in the apoptotic fraction, and cell cycle arrest PMC7322626
MINO 10 μM 8 h Nutlin-3 induced cell cycle arrest and reduced cell viability in the mutant TP53 MINO cells PMC7322626
B-cell precursor acute lymphoblastic leukemia cells 0–10 µM To evaluate the cytotoxic effect of nutlin-3 on ALL cells with different p53 status and MDM2 expression, it was found that ALL cells with wt-p53 are sensitive to nutlin-3, while ALL cells with p53-mutant or -null phenotype are not sensitive to nutlin-3 PMC3477706
Primary acute lymphoblastic leukemia cells 0–10 µM To analyze the cytotoxic effect of nutlin-3 on primary ALL cells, it was found that primary ALL cells with wt-p53 are sensitive to nutlin-3, while primary ALL cells with p53 mutation are not sensitive to nutlin-3 PMC3477706
UKF-NB-3rNutlin10μM cells 10 μM To study the effects of RITA on p53 activation and apoptosis, results showed RITA induced p53 activation and apoptosis PMC3358013
BHK cells 10 µM ∼16 hours Detection of p53-GFP ubiquitination and its inhibition by Nutlin-3 PMC9757074
SJSA-1 cells 10 μM 2-3 weeks Test the long-term effect of Nutlin on SJSA-1 cells, results showed no colony formation PMC3347888
ARPE-19 cells 0.1–50 μM 24 and 48 hours To evaluate the effects of Nutlin-3 on cell viability and proliferation. Results showed that Nutlin-3 significantly reduced cell viability and proliferation in a dose-dependent manner at both 24 and 48 hours. PMC11018138
PAEC cells 10 µM 24 hours Nutlin-3 increases p53 levels and induces PPARγ-p53 complex formation PMC7908816
HCT116 (colon cancer cells) 20 μM 24 hours Nutlin-3 enhances the bortezomib sensitivity of p53-defective cancer cells by inducing paraptosis leading to cell death. PMC5579507
T98G (glioblastoma cells) 30 μM 24 hours Nutlin-3 enhances the bortezomib sensitivity of p53-defective cancer cells by inducing paraptosis leading to cell death. PMC5579507
HeLa (cervical cancer cells) 30 μM 24 hours Nutlin-3 enhances the bortezomib sensitivity of p53-defective cancer cells by inducing paraptosis leading to cell death. PMC5579507
DLD-1 (colon cancer cells) 30 μM 24 hours Nutlin-3 enhances the bortezomib sensitivity of p53-defective cancer cells by inducing paraptosis leading to cell death. PMC5579507
MDA-MB 435S (breast cancer cells) 30 μM 24 hours Nutlin-3 enhances the bortezomib sensitivity of p53-defective cancer cells by inducing paraptosis leading to cell death. PMC5579507
A549-Atg5-null 10 μM 24 hours To evaluate the effect of Nutlin-3 on PD-L1 expression, results showed PD-L1 expression was higher in Atg5-null cells PMC7457494
A549-Atg5-wt 10 μM 24 hours To evaluate the effect of Nutlin-3 on PD-L1 expression, results showed PD-L1 expression was lower in Atg5-wt cells PMC7457494
L02 cells 10 μM 48 hours Nutlin-3 did not change IFI16 subcellular localization in L02 cells. PMC4326783
Hep3B cells 10 μM 48 hours Nutlin-3 did not induce ectopic expression of IFI16 protein in Hep3B cells. PMC4326783
Huh-7 cells 10 μM 48 hours Nutlin-3 did not induce ectopic expression of IFI16 protein in Huh-7 cells. PMC4326783
A375 p53-null 10 μM 24 hours To evaluate the effect of Nutlin-3 on cell surface expression of CD276 and PD-L1, results showed Nutlin-3 did not induce CD276 expression in p53-null cells PMC7457494
A375 p53-wt 10 μM 24 hours To evaluate the effect of Nutlin-3 on cell surface expression of CD276 and PD-L1, results showed Nutlin-3 induced CD276 expression in a p53-dependent manner PMC7457494
HCT116 p53-null 10 μM 24 hours To evaluate the effect of Nutlin-3 on cell surface expression of CD276 and PD-L1, results showed Nutlin-3 did not induce CD276 expression in p53-null cells PMC7457494
HCT116 p53-wt 10 μM 24 hours To evaluate the effect of Nutlin-3 on cell surface expression of CD276 and PD-L1, results showed Nutlin-3 induced CD276 expression in a p53-dependent manner PMC7457494
OVCAR-3 ovarian cancer cells 20 μM 24 hours OVCAR-3 cells harboring mutant p53 were not sensitized to rhTRAIL or D269H/E195R by nutlin-3, whereas cisplatin pre-treatment increased the apoptotic effect of both ligands. PMC3833221
Lovo colon cancer cells 5-20 μM 24 hours Nutlin-3 dose-dependently enhanced p53, p21 and MDM2 levels, indicating transcriptional activation of p53 due to the effective disruption of the MDM2–p53 interaction. DR5 protein levels and membrane expression were also increased. PMC3833221
H460 non-small cell lung cancer cells 5-20 μM 24 hours Nutlin-3 dose-dependently enhanced p53, p21 and MDM2 levels, indicating transcriptional activation of p53 due to the effective disruption of the MDM2–p53 interaction. DR5 protein levels and membrane expression were also increased. PMC3833221
A2780 ovarian cancer cells 5-20 μM 24 hours Nutlin-3 dose-dependently enhanced p53, p21 and MDM2 levels, indicating transcriptional activation of p53 due to the effective disruption of the MDM2–p53 interaction. DR5 protein levels and membrane expression were also increased. PMC3833221
SJSA-1 cells 10 μM 3 days Test the apoptosis-inducing effect of Nutlin on SJSA-1 cells, results showed ~40% of cells underwent apoptosis PMC3347888
SAOS-2 cells 6 μM 4 or 6 hours To investigate the effect of Nutlin-3 on p53 acetylation, results showed Nutlin-3 enhanced p53 acetylation PMC4032636
U-2 OS cells 5 µM 45 hours Nutlin-3a in combination with actinomycin D significantly enhanced FASLG-induced apoptosis. PMC11416401
A549 cells 5 µM 45 hours Nutlin-3a in combination with actinomycin D significantly enhanced FASLG-induced apoptosis, activating caspase-8, caspase-9, and caspase-3. PMC11416401
SMMC7721/As 20 μM 48 hours Combination of Nutlin-3 and arsenic trioxide significantly inhibited proliferation and induced apoptosis in SMMC7721/As cells PMC4046148
HepG2/As 20 μM 48 hours Combination of Nutlin-3 and arsenic trioxide significantly inhibited proliferation and induced apoptosis in HepG2/As cells PMC4046148
SMMC-7721 cells 10 μM 48 hours Nutlin-3 significantly increased the expression levels of IFI16 and IFNB1 mRNA, and partially redistributed chromatin-bound IFI16 protein to the cytoplasm. These effects were blocked by pretreatment with pifithrin-α, a p53 inhibitor. PMC4326783
H1299 cells 6 μM 6 hours To investigate the effect of Nutlin-3 on p53 acetylation, results showed Nutlin-3 enhanced p53 acetylation PMC4032636
MOLM-13 cells 6 μM 6 hours To investigate the effect of Nutlin-3 on p53 acetylation, results showed Nutlin-3 enhanced p53 acetylation PMC4032636
UoCB6 cells 1–10 μM Nutlin-3 treatment led to a substantial accumulation of the p53 protein as well as the expression of its direct targets p21, MDM2 and the pro-apoptotic BAX and PUMA proteins. PMC3948158
REH cells 1–10 μM Nutlin-3 treatment significantly reduced viability and increased apoptosis, while inducing p21 expression, leading to an increased proportion of cells in the G0/G1 phase. PMC3948158
AT-2 cells 1–10 μM Nutlin-3 treatment led to a substantial accumulation of the p53 protein as well as the expression of its direct targets p21, MDM2 and the pro-apoptotic BAX and PUMA proteins. PMC3948158

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice EC-Bmpr2−/− mice Intraperitoneal injection 12 mg/kg Daily for two weeks Nutlin-3a restored the PPARγ-p53 complex in EC-Bmpr2?/? mice, induced target gene expression, regenerated pulmonary microvessels, and reversed pulmonary hypertension. PMC7908816
Nude mice Orthotopic hepatic tumor model Oral 200 mg/kg Twice daily for 28 days To evaluate the anti-tumor effect of Nutlin-3 combined with arsenic trioxide on orthotopic hepatic tumors in nude mice, results showed that the combination significantly inhibited tumor growth and lung metastasis. PMC4046148
Mice Lipo-246 xenograft model Oral gavage 37.5 mg/kg Days 1-5 of each week for up to 3 weeks The combination of idasanutlin and carfilzomib significantly slowed tumor growth and improved survival. PMC10391328
BALB/c Nude mice RT4 and HEI-193 schwannoma cell xenograft models Intraperitoneal injection 40 mg/kg Once daily for 14 days Nutlin-3 combined with MG-132 significantly inhibited the growth of schwannoma xenografts and induced apoptosis in tumour cells. PMC6197711

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.72mL

0.34mL

0.17mL

8.60mL

1.72mL

0.86mL

17.20mL

3.44mL

1.72mL

References

 

Historical Records

Categories